MediGene

MediGene AG
Aktiengesellschaft
Traded as FWB: MDG1
Industry Biotechnology
Predecessor Munich Gene Center
Founded 1994
Headquarters Martinsried, Germany
Key people
 Frank Mathias (CEO), Horst Domdey (Chairman of the supervisory board)
Products Pharmaceuticals for treatment of cancer and autoimmune diseases
Revenue €37.9 million (2009)[1]
Decrease (€19.6 million) (2009)[1]
Profit Decrease (€22.0 million) (2009)[1]
Number of employees
 110 (end 2009)[1]
Website www.medigene.com

MediGene AG is a German biotechnology company established in 1994. It is involved in the development of drugs to treat breast and pancreatic cancer.[2] The company has two marketed products: Eligard (leuprorelin) for prostate cancer and Veregen (sinecatechins) for genital warts. It has three other products in clinical development for the treatment of hormone-resistant breast cancer, pancreatic cancer, and rheumatoid arthritis.

References

  1. ↑ 1.0 1.1 1.2 1.3 "Annual Report 2009". MediGene. Retrieved 22 August 2010.
  2. ↑ "MediGene drug extends pancreatic cancer survival". Reuters. 2008-09-18.

External links